Resmetirom improved HRQOL versus placebo in early MASH, particularly abdominal symptoms, disease-related worry, and health distress, with onset by week 24 and durability through week 52. Baseline ...
Introduction Psychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results